Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Lowy Website

Douglas R. Lowy, M.D.

Selected Publications

1)  Safaeian M, Kemp TJ, Pan DY, Porras C, Cecilia Rodriguez A, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica Vaccine Trial.
Hum Vaccin Immunother. 9, 2013.
2)  Day PM, Thompson CD, Schowalter RM, Lowy DR, Schiller JT.
Identification of a Role for the trans-Golgi Network in Human Papillomavirus 16 Pseudovirus Infection.
J. Virol. 87: 3862-70, 2013.
3)  Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang H, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB.
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
J. Virol. [Epub ahead of print], 2013.
4)  Day PM, Pang YS, Kines RC, Thompson CD, Lowy DR, Schiller JT.
An HPV in vitro neutralization assay that recapitulates the in vivo process of infection provides a sensitive measure of L2 infection-inhibiting antibodies.
Clin Vaccine Immunol. [Epub ahead of print], 2012.
5)  Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE.
Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Vaccine. 30: 6016-9, 2012.
6)  Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI, Lowy DR.
Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
Cancer Res. 72: 4405-16, 2012.
7)  Qian X, Durkin ME, Wang D, Tripathi BK, Olson L, Yang XY, Vass WC, Popescu NC, Lowy DR.
Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
Cancer Res. 72: 5900-11, 2012.
8)  Çuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, Lowy DR, Schiller JT.
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
J. Clin. Invest. 122: 4606-20, 2012.
9)  Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA.
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).
Vaccine. 31: 165-70, 2012.
10)  Handisurya A, Day PM, Thompson CD, Buck CB, Kwak K, Roden RB, Lowy DR, Schiller JT.
Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.
Virology. 433: 385-94, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 4/18/2013.